CAPRICOR THERAPEUTICS, INC. CAPR

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy ("DMD"), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need. Since our inception, we have devoted substantial resources to the development of our lead product candidate, Deramiocel, a cell therapy designed to address the cardiac and skeletal muscle complications associated with DMD, as well as to advancing our exosome-based platform, developing manufacturing capabilities and supporting our research and development activities. Our Biologics License Application ("BLA") for Deramiocel for the treatment of DMD is currently under review by the U.S. Food and Drug Administration ("FDA"), with a Prescription Drug User Fee Act ("PDUFA") target action date of August 22, 2026, for potential approval in the United States. We currently have no products approved for commercial sale. Our ability to generate product revenue and achieve profitability will depend on the successful development, regulatory approval and commercialization of Deramiocel and any other product candidates we may develop. If approved, we intend to commercialize Deramiocel in the United States and may seek commercialization through strategic partners in other select international markets.

Last close 5.93 2026-10-23
Market cap $344.8M 2026-06-30 share count
52-week range 2.96 - 40.37

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.26

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $0$22.3M$25.2M$2.6M$244.9K$310.2K$1.0M$1.7M$2.7M$4.0M
R&D $84.5M$50.0M$36.4M$21.8M$13.6M$8.5M$5.1M$12.1M$10.8M$16.0M
SG&A $23.7M$14.9M$12.8M$10.4M$7.6M$5.5M$3.6M$4.9M$4.8M$4.9M
Total operating expenses $108.1M$64.8M$49.3M$32.2M$21.2M$14.0M$8.7M$17.0M$15.5M$21.0M
Operating income -$108.1M-$42.6M-$24.1M-$29.7M-$20.9M-$13.7M-$7.7M-$15.3M-$12.9M-$17.0M
Interest expense $3.0M$0—————$0$398.8K$344.7K
Pre-tax income -$105.0M-$40.5M————————
Income tax $1.6K$1.6K————————
Net income -$105.0M-$40.5M-$22.3M-$29.0M-$20.0M-$13.7M-$7.6M-$15.2M$2.4M-$18.8M
EPS, basic -2.26-1.15-0.83-1.18-0.87-0.88——0.10-1.01
EPS, diluted -2.26-1.15-0.83-1.18-0.87-0.88-2.06-5.170.09-1.01
Shares, diluted (wtd. avg.) 46.5M35.2M26.8M24.6M23.1M15.6M3.7M2.9M26.8M18.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $287.8M$11.3M$14.7M$9.6M$34.9M$32.7M$3.9M$4.5M$6.9M$4.6M
Short-term investments $30.3M$140.2M$24.8M$31.8M$0—$6.0M$3.0M$8.0M$13.0M
Total current assets $322.9M$163.4M$50.9M$42.9M$36.4M$33.7M$10.5M$8.5M$15.7M$18.1M
Property, plant and equipment $18.3M$5.6M$5.6M$4.6M$1.8M$850.8K$442.8K$574.2K$372.1K$435.3K
Other intangibles ————$0$2.2K$6.5K$49.8K$93.0K$142.3K
Total assets $355.9M$170.5M$58.7M$50.1M$41.3M$34.6M$11.1M$9.2M$16.3M$18.7M
Accounts payable $1.7M$3.3M$6.3M$4.8M$3.1M$2.7M$898.0K$1.1M$1.5M$3.0M
Total current liabilities $35.8M$21.0M$31.3M$23.6M$4.1M$3.0M$898.0K$1.3M$1.7M$4.9M
Total liabilities $50.2M$25.0M$36.1M$38.3M$10.0M$6.4M$4.3M$4.6M$5.0M$22.8M
Retained earnings -$304.9M-$199.8M-$159.4M-$137.1M-$108.1M-$88.0M-$74.4M-$66.7M-$51.5M-$54.0M
Total equity $305.8M$145.5M$22.6M$11.8M$31.4M$28.2M$6.8M$4.6M$11.2M-$4.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$69.8M-$40.0M-$25.6M$4.9M-$16.8M-$10.1M-$6.8M-$13.9M-$14.2M-$14.5M
Depreciation and amortisation $1.9M$1.4M$1.1M$533.1K$245.7K$143.9K$172.0K$157.7K$144.2K$125.7K
Stock-based compensation —$9.8M$7.4M$4.5M$3.0M$2.0M$701.0K$1.7M$1.7M$2.0M
Capital expenditure $2.9M$1.2M$1.3M$2.0M$1.2M$547.6K$0$316.5K$32.2K$192.0K
Investing cash flow $97.5M-$116.2M$5.1M-$35.1M-$1.2M$5.4M-$3.0M$4.7M$5.0M-$5.2M
Financing cash flow $248.9M$152.8M$25.6M$4.9M$20.2M$33.4M$9.2M$6.9M$11.6M$18.6M
Buybacks —————$0$193$0——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-042070.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -150M -100M -50M 0 50M Revenue, FY2016: 4M Net income, FY2016: -18.8M Revenue, FY2017: 2.7M Net income, FY2017: 2.4M Revenue, FY2018: 1.7M Net income, FY2018: -15.2M Revenue, FY2019: 1M Net income, FY2019: -7.6M Revenue, FY2020: 310.2K Net income, FY2020: -13.7M Revenue, FY2021: 244.9K Net income, FY2021: -20M Revenue, FY2022: 2.6M Net income, FY2022: -29M Revenue, FY2023: 25.2M Net income, FY2023: -22.3M Revenue, FY2024: 22.3M Net income, FY2024: -40.5M Revenue, FY2025: 0 Net income, FY2025: -105M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $4.0M $2.7M $1.7M $1.0M $310.2K $244.9K $2.6M $25.2M $22.3M $0
Gross profit — — — — — — — — — —
Net income -$18.8M $2.4M -$15.2M -$7.6M -$13.7M -$20.0M -$29.0M -$22.3M -$40.5M -$105.0M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%